UiPath (NYSE:PATH) PT Raised to $30.00

UiPath (NYSE:PATH) had its price objective raised by Bank of America from $26.00 to $30.00 in a research report report published on Thursday, Benzinga reports. The brokerage currently has a buy rating on the healthcare company’s stock.

Other equities analysts have also recently issued reports about the stock. Scotiabank boosted their target price on shares of UiPath from $29.00 to $30.00 and gave the company a sector perform rating in a research note on Thursday. William Blair began coverage on shares of UiPath in a report on Tuesday, January 2nd. They issued an outperform rating for the company. DA Davidson lifted their price objective on shares of UiPath from $20.00 to $24.00 and gave the stock a neutral rating in a research report on Thursday. JPMorgan Chase & Co. upgraded shares of UiPath from a neutral rating to an overweight rating and boosted their price target for the stock from $22.00 to $28.00 in a research note on Thursday. Finally, Barclays upped their target price on shares of UiPath from $23.00 to $25.00 and gave the stock an equal weight rating in a research report on Friday. Nine investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $27.13.

UiPath Stock Performance

PATH stock traded up $0.32 during trading on Thursday, hitting $23.07. 9,842,354 shares of the company’s stock traded hands, compared to its average volume of 10,074,664. The business has a fifty day simple moving average of $23.52 and a 200 day simple moving average of $20.70. The stock has a market capitalization of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97. UiPath has a 52 week low of $12.38 and a 52 week high of $27.87.

Insider Buying and Selling at UiPath

In other news, Director Rich Wong sold 200,000 shares of UiPath stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $23.12, for a total value of $4,624,000.00. Following the sale, the director now directly owns 429,418 shares in the company, valued at approximately $9,928,144.16. The sale was disclosed in a filing with the SEC, which is available through this link. In other UiPath news, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the completion of the sale, the director now owns 429,418 shares of the company’s stock, valued at $9,928,144.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $22.47, for a total value of $359,520.00. Following the transaction, the chief financial officer now directly owns 103,505 shares of the company’s stock, valued at $2,325,757.35. The disclosure for this sale can be found here. Insiders have sold a total of 411,000 shares of company stock valued at $9,418,670 in the last 90 days. Corporate insiders own 31.03% of the company’s stock.

Hedge Funds Weigh In On UiPath

A number of large investors have recently bought and sold shares of PATH. Mark Sheptoff Financial Planning LLC acquired a new stake in UiPath in the fourth quarter valued at $25,000. HighMark Wealth Management LLC purchased a new stake in UiPath during the 4th quarter worth $27,000. Tyler Stone Wealth Management acquired a new position in UiPath in the 2nd quarter worth $28,000. Cypress Capital Management LLC WY bought a new stake in shares of UiPath during the 4th quarter valued at about $29,000. Finally, Fifth Third Bancorp grew its position in UiPath by 2,005.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock worth $34,000 after purchasing an additional 1,905 shares during the last quarter. Institutional investors and hedge funds own 59.04% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.